Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, aimed at treating atopic dermatitis.
ENS-002 is being developed for atopic dermatitis by targeting Staphylococcus aureus (S. aureus), which is a key skin inflammation driver.
Go deeper with GlobalData
Concerto Biosciences leveraged its screening technology, kChip, for the discovery of ENS-002. This platform can screen millions of microbial combinations, creating a vast dataset of microbial interactions. These data provide precise, predictive insights into microbial behaviour.
The first-in-human study is set to enrol approximately nine participants across three cohorts. These cohorts will receive increasing dose concentrations and frequencies to assess the product’s safety, tolerability, and efficacy in controlling S. aureus and treating atopic dermatitis.
Clinical trial sites for topical ENS-002 for atopic dermatitis in adults (EnSync) are currently open for enrolment.
In June this year, the US Food and Drug Administration (FDA) accepted the investigational new drug (IND) application, allowing the Phase I trial of Ensemble No.2 (ENS-002) to proceed.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe hypothesis behind ENS-002’s development stemmed from insights into the role of the skin’s microbial ecology in atopic dermatitis.
Using kChip, the company identified three microbial strains that synergistically encourage S. aureus to transition from a harmful state to a more benign one after generating over six million unique microbial combinations.
Concerto Biosciences CEO Cheri Ackerman said: “For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care.”
“This clinical milestone marks a promising step forward, not only in managing a challenging skin condition but also in demonstrating the potential of precisely selected microbial combinations to address complex diseases rooted in microbiome deficiencies.
“Demonstration of this therapeutic approach could change the way we think about the mechanisms and therapeutic possibilities in a wide variety of diseases.”
